November/December 2017: Volume 18 Number 11/12
28 November 2017. Related: Editorial.
2017
PrEP for women and PrEP in the UK: new leaflets
28 November 2017. Related: Supplements.
Guide to changing treatment: what to do if your viral load rebounds
28 November 2017. Related: Supplements.
i-Base 2017 appeal: we need your help….
28 November 2017. Related: Editorial.
16th European AIDS Conference (EACS 2017)
28 November 2017. Related: Conference reports.
Fostemsavir in highly treatment-experienced participants: 24-week phase 3 results
28 November 2017. Related: Conference reports, Antiretrovirals.
D/C/F/TAF: phase 3 naive results and splitting PI-based FDC tablets
28 November 2017. Related: Conference reports, Antiretrovirals.
Dolutegravir-based dual therapy as switch option in multiple studies
28 November 2017. Related: Conference reports, Treatment strategies.
Switch study shows F/TAF non-inferior to continuing abacavir/3TC
28 November 2017. Related: Conference reports, Antiretrovirals, Treatment strategies.
Twice-daily tenofovir alafenamide dose might overcome interaction with rifampicin
28 November 2017. Related: Conference reports, PK and drug interactions, TB coinfection.
No impact on bioavailability of D/C/F/TAF when tablet is split but TAF absorption is reduced if crushed
28 November 2017. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Studies on dolutegravir and sleep, cardiovascular and CNS side effects, and risk of IRIS
28 November 2017. Related: Conference reports, Side effects.
Dolutegravir use in pregnancy: results from small Belgian cohort
28 November 2017. Related: Conference reports, Pregnancy.
No transmissions from breastfeeding in Tanzania cohort from mothers with undetectable viral load
28 November 2017. Related: Conference reports, Pregnancy.
Updated European guidelines launched at EACS 2017
28 November 2017. Related: Conference reports, Guidelines.
ABX464 nudges viral reservoir but not time to viral rebound
28 November 2017. Related: Conference reports, Antiretrovirals, Cure-related research.
8th International Workshop on HIV & Ageing, 2–3 October 2017, New York
28 November 2017. Related: Conference reports.
Selected webcasts from 8th HIV and ageing workshop
28 November 2017. Related: Conference reports, Ageing and life expectancy.
8th HIV and Ageing Workshop: reports at natap.org
28 November 2017. Related: Conference reports, Ageing and life expectancy.
9th IAS Conference on HIV Science (IAS 2017)
28 November 2017. Related: Conference reports.
Reassuring French data using raltegravir during pregnancy
28 November 2017. Related: Conference reports, Pregnancy.
Earlier ART reduces infant mortality in South Africa but risk of death and loss to follow up still high
28 November 2017. Related: Conference reports, Paediatric care.
Screening HIV positive pregnant women for TB in South Africa increased detection by 10-fold
28 November 2017. Related: Conference reports, Women's health, Pregnancy, HIV prevention and transmission.
Long-acting ART for children is a deferred priority despite achievable dosing
28 November 2017. Related: Antiretrovirals, Paediatric care.
Sexual and reproductive health: draft UK guidelines online for comment (2017)
28 November 2017. Related: Guidelines.
Estimating the total size of the HIV reservoir
28 November 2017. Related: Cure-related research.
Reducing rates of HIV-related cancer in US from 1996-2012
28 November 2017. Related: Coinfections and complications.
Effects of the anti-inflammatory antibody canakinumab on heart disease and cancer: implications for HIV?
28 November 2017. Related: Side effects, Coinfections and complications, Basic science and immunology.
MSF secures generic hepatitis C treatment at $120 per course
28 November 2017. Related: Treatment access, Hepatitis coinfection, Other news.
Conference materials online
28 November 2017. Related: On the web.
Recent peer-review studies
28 November 2017. Related: On the web.
Updates from the PrEP IMPACT study – November 2017
28 November 2017. Related: HIV prevention and transmission, Research studies.
November/December 2017: Volume 18 Number 11/12
28 November 2017. Related: PDFs.
Coformulated dolutegravir plus rilpivirine approved in US (Juluca)
24 November 2017. Related: Antiretrovirals.
Darunavir-based single pill FDC approved in EU (Symtuza)
24 November 2017. Related: Antiretrovirals.
September/October 2017: Volume 18 Number 9/10
1 October 2017. Related: Editorial.
Experts disagree with controversial BMJ support for older HIV drugs in pregnancy
1 October 2017. Related: Special reports, Women's health, Pregnancy.
New guides to PrEP
1 October 2017. Related: Editorial, Supplements, HIV prevention and transmission.
The evidence for U=U (Undetectable = Untransmittable): why negligible risk is zero risk
1 October 2017. Related: Special reports, HIV prevention and transmission.
9th IAS Conference on HIV Science (IAS 2017)
1 October 2017. Related: Conference reports.
Dual therapy with darunavir/r plus lamivudine as first-line ART
1 October 2017. Related: Conference reports, Antiretrovirals.
Dual therapy with dolutegravir plus lamivudine as first-line ART
1 October 2017. Related: Conference reports, Antiretrovirals.
Once-daily raltegravir: 96-week results from the ONCEMRK study
1 October 2017. Related: Conference reports, Antiretrovirals.
New IPERGAY analysis shows on-demand PrEP dosing works with less frequent sex
1 October 2017. Related: Conference reports, HIV prevention and transmission.
On-demand dosing for PrEP is highly effective in French expanded access programme
1 October 2017. Related: Conference reports, HIV prevention and transmission.
Psychological impact of PrEP: beyond efficacy and cost-effectiveness
1 October 2017. Related: Conference reports, HIV prevention and transmission.
Early ART and testing HIV negative with rapid HIV tests
1 October 2017. Related: Conference reports, HIV prevention and transmission.
Report from the IAS HIV Cure & Cancer Forum, 22–23 July 2017, Paris
1 October 2017. Related: Conference reports, Cancer and HIV, Cure-related research.
Generic dolutegravir-based FDCs at US $75 a year for low- and middle-income countries
1 October 2017. Related: Treatment access.
UK donates well to the Global Fund, but slashed bilateral aid for HIV
1 October 2017. Related: Treatment access.
Dozens of countries left out of new PEPFAR strategy, threatening the global AIDS response
1 October 2017. Related: Treatment access.
Gilead uses voucher to speed FDA review of bictegravir
1 October 2017. Related: Antiretrovirals.
BHIVA challenges BMJ recommendations on ART during pregnancy: tenofovir still strongly recommend
1 October 2017. Related: Pregnancy.
STOPAIDS reviews DFID’s work on HIV and AIDS
1 October 2017. Related: Other news.
UK PrEP guidelines: online for comment (Oct 2017)
1 October 2017. Related: Guidelines, HIV prevention and transmission.
US IDSA HIV pain management guidelines (2017)
1 October 2017. Related: Guidelines.
NHS access to PrEP in the UK: country update
1 October 2017. Related: Treatment access, HIV prevention and transmission.
Generic PrEP in France and Scotland challenges access across the UK
1 October 2017. Related: Treatment access, HIV prevention and transmission.
PrEP use in adolescent gay and bisexual men: US study shows need for easier access and easier PrEP
1 October 2017. Related: HIV prevention and transmission.
Enhanced OI prophylaxis reduces mortality when starting ART late
1 October 2017. Related: Coinfections and complications.
Increased frequency and progression of kidney disease in HIV positive people
1 October 2017. Related: Side effects, Coinfections and complications.
HIV and drug adherence: RITA!
1 October 2017. Related: On the web.
September/October 2017: Volume 18 Number 9/10
1 October 2017. Related: PDFs.
July/August 2017: Volume 18 Number 7/8
14 August 2017. Related: Editorial.
HIV Pipeline Report (2017)
14 August 2017. Related: Supplements.